Emyria Ltd has released a press release.
Emyria Launches Drug Development Program Based on RWE
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Emyria Partners with Thought Leaders in Psychedelic Therapy
- Emyria Enters Data Deal with ZLD to Support Autism Trial
- Webinar on Global Partnership with Sapphire Medical Clinics
- Emyria Signs Real-World Data Agreement with Zelira
- Preliminary Final Report and Full Year Statutory Accounts
Later from Emyria
- Emyria Sees Strong Interest in IBS Study
- Emyria to Benefit from Final TGA Ruling on CBD Medicines
- Emyria Pursuing Registration of EMD-003 in CY2021
- FDA Position on RWE to Guide Registration
- Emyria wins digital health monitoring grant with UWA
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria